Stereotaxis, Inc. (STXS)
NYSEAMERICAN: STXS · Real-Time Price · USD
2.430
+0.100 (4.29%)
At close: Dec 4, 2025, 4:00 PM EST
2.430
0.00 (0.00%)
After-hours: Dec 4, 2025, 8:00 PM EST
Stereotaxis Revenue
Stereotaxis had revenue of $7.46M in the quarter ending September 30, 2025, a decrease of -18.83%. This brings the company's revenue in the last twelve months to $30.08M, up 19.62% year-over-year. In the year 2024, Stereotaxis had annual revenue of $26.92M with 0.55% growth.
Revenue (ttm)
$30.08M
Revenue Growth
+19.62%
P/S Ratio
7.16
Revenue / Employee
$216,367
Employees
139
Market Cap
226.78M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 26.92M | 147.00K | 0.55% |
| Dec 31, 2023 | 26.77M | -1.38M | -4.89% |
| Dec 31, 2022 | 28.15M | -6.87M | -19.63% |
| Dec 31, 2021 | 35.02M | 8.39M | 31.51% |
| Dec 31, 2020 | 26.63M | -2.27M | -7.86% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
STXS News
- 10 days ago - Stereotaxis to Participate in Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 23 days ago - Stereotaxis, Inc. (STXS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Stereotaxis Reports 2025 Third Quarter Financial Results - GlobeNewsWire
- 24 days ago - GenesisX Robotic Magnetic Navigation System Receives U.S. FDA Clearance - GlobeNewsWire
- 6 weeks ago - Stereotaxis to Report Third Quarter 2025 Financial Results on November 11, 2025 - GlobeNewsWire
- 7 weeks ago - Stereotaxis Announces EU Launch and 510(k) Submission for Synchrony System to Modernize Interventional Cath Labs - GlobeNewsWire
- 7 weeks ago - Stereotaxis & CardioFocus Collaborate to Advance Robotic Pulsed Field Ablation for Cardiac Arrhythmias - GlobeNewsWire
- 2 months ago - Erasmus Medical Center Advances Cardiovascular Care with Genesis Robotic System - GlobeNewsWire